Southeast Asia

NOT Open Access | Serratia marcescens secretes proteases and chitinases with larvicidal activity against Anopheles dirus

Tags:

vector control, malaria, serratia marcescens, Anopheles dirus, Southeast Asia

Author(s):

Jupatanakul N, Pengon J, Selisana SMG, Choksawangkarn W, Jaito N, Saeung A, Bunyong R, Posayapisit N, Thammatinna K, Kalpongnukul N, Aupalee K, Pisitkun T, Kamchonwongpaisan S

Reference:

Acta Trop. 2020 Aug 28:105686

Vector control, the most efficient tool to reduce mosquito-borne disease transmission, has been compromised by the rise of insecticide resistance. Recent studies suggest the potential of mosquito-associated microbiota as a source for new biocontrol agents or new insecticidal chemotypes. In this study, we identified a strain of Serratia marcescens that has larvicidal activity against Anopheles dirus, an important malaria vector in Southeast Asia.

Population genomics identifies a distinct Plasmodium vivax population on the China-Myanmar border of Southeast Asia

Tags:

population genomics, Plasmodium vivax, chloroquine resistance, Southeast Asia

Author(s):

Brashear AM, Fan Q, Hu Y, Li Y, Zhao Y, Wang Z, Cao Y, Miao J, Barry A, Cui L.

Reference:

PLoS Negl Trop Dis 14(8): e0008506

Plasmodium vivax has become the predominant malaria parasite and a major challenge for malaria elimination in the Greater Mekong Subregion (GMS). Yet, our knowledge about the evolution of P. vivax populations in the GMS is fragmental. We performed whole genome sequencing on 23 P. vivax samples from the China-Myanmar border (CMB) and used 21 high-coverage samples to compare to over 200 samples from the rest of the GMS.

NOT Open Access | Efficacy and Safety of a Naphthoquine-Azithromycin Co-Formulation for Malaria Prophylaxis in Southeast Asia: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial

Tags:

naphthoquine-azithromycin, malaria, prophylaxis, plasmodium infections, Southeast Asia, pacebo-controlled trial

Author(s):

Yang H, Wang J, Cui L, et al.

Reference:

Clin Infect Dis. 2020 Jul 20:ciaa1018

A prophylactic antimalarial drug that is both effective for protection and improves compliance is in high demand.

NOT Open Access | Is the Epidemiology of Plasmodium knowlesi Changing, and What Does This Mean for Malaria Control in Southeast Asia?

Tags:

Plasmodium knowlesi, malaria control, Southeast Asia

Author(s):

Karunajeewa H, Berman J

Reference:

Clinical Infectious Diseases, Volume 70, Issue 3, 1 February 2020, Pages 368–369

It has long been clear that the “monkey-malaria” species, Plasmodium knowlesi, is capable of infecting humans. Its name comes from Robert Knowles, the British parasitologist who first demonstrated experimental monkey–human transmission and pioneered its use as “malaria therapy” for syphilis and leprosy from as early as 1932 [1].

Search form

You are here